Nucleoside Analogs Archives

Merck’s COVID pill is last choice for U.S. patients, global use varies

Antibodies, Antivirals, COVID-19 treatment pill, Doctors, Health Systems, India, Merck, Molnupiravir, National Institutes of Health, Nucleoside Analogs, Pfizer, Pharmacies, Philippines, Reuters, United States

Merck & Co.’s new antiviral pill – once touted as a potential game changer for treating COVID-19 – is the last choice among four available options for at-risk patients given its relatively low efficacy and potential safety issues, U.S. doctors, healthcare systems and pharmacies told Reuters.

January 31, 2022/by Reuters Health

New Drug Discovery Process Could Significantly Cut Development Time

Cells, Coronavirus Cases, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Treatment Acceleration Program (CTAP), Drug Development, Drug Discovery, FDA, Medical Journals, Nucleoside Analogs, Papers, Science, Scientists, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Synthesis

A paper published in the journal Science on August 8 suggests that it may be possible to speed up the drug discovery process.

August 11, 2020/by Andrew Humphreys